Increased serum E2 is associated with compensatory mechanisms that arise in conjunction with defective estrogen signaling in normal breast tissue36,37, and elevated serum E2 has also been reported in estrogen insensitive triple-negative breast cancer (TNBC) patients as compared to those with ER+ tumors35. Here, ESR1 is linked to triple-negative breast carcinoma.